Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.63) by 11.11 percent. This is a 15.15 percent increase over losses of $(0.66) per share from the same period last year.